FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

1. Name and Address of Reporting Person*

September 30, 2016

GN 2016 Organo 10-Year GRAT u/a/d

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden esponse: 0.5

> > 7. Nature of Indirect Beneficial Ownership (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Instruc	ction 1(b).	nue. See		Filed							ities Exchang					nours	s per r	esponse:	0.5
1. Name and Address of Reporting Person* ERANI ALBERT			or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol Organogenesis Holdings Inc. [ORGO] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)																
(Last) (First) (Middle) C/O RUGBY REALTY CO., INC. 300 LIGHTING WAY, STE 210				3. Date of Earliest Transaction (Month/Day/Year) 06/06/2022 Director X 10% Owner Officer (give title below) Other (specify below)															
(Street) SECAUCUS NJ 07094			4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person							
(City)	(St	rate) (Zip)																
		Table	l - No	on-Deriva	ative	Secu	ırities	Ac	quirec	l, Dis	sposed of	, or E	Benefi	ciall	y Own	ed			
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed O Code (Instr. 5)		s Acquired (A) or of (D) (Instr. 3, 4 an		and Securities Beneficial Owned Fo		ies cially Following	For (D)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficia Ownershi				
									Code	v	Amount	(A) (D)	or Pric	Price		Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)
	Common St			06/06/2	2022				S		100,000	D		41 ⁽¹⁾	<u> </u>	48,027(4)	L	D	
	Common St			06/07/2					S		50,000	D	-	49 ⁽²⁾	<u> </u>	98,027(4)	┝	D	
Class A C	Common St		ble II	06/08/2		ocur	itios	A car	s uired	Dien	20,000 posed of,	or Be		39 ⁽³⁾		78,027 ⁽⁴⁾		D	
			DIC II								convertib				OWITE	u			
1. Title of Derivative Security (Instr. 3) 2. Conversio or Exercise Price of Derivative Security		3. Transaction Date (Month/Day/Year)	Execu if any	a. Deemed tecution Date, any onth/Day/Year)		action (Instr.			6. Date Exerc Expiration D (Month/Day/		ate	7. Title and Amount of Securities Underlying Derivative Security (In 3 and 4)		De Se (In	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transactior (Instr. 4)	Ow For Dir or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Benefic Owners (Instr. 4
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amoun or Numbe of Shares	r					
		f Reporting Person	*																
EKAN	I ALBER	<u>.1</u> 				-													
(Last)	GBY REAI	(First) LTY CO., INC.	(M	liddle)															
		AY, STE 210																	
(Street)	CUS	NJ	07	7094															
(City)		(State)	(Zi	ip)		_													
	nd Address o loldings,	f Reporting Person	*																
		(First) LTY CO., INC. AY, STE 210	(M	liddle)															
(Street) SECAUC	CUS	NJ	07	7094															
(City)		(State)	(Zi	ip)															

(Last)	(First)	(Middle)						
35 SAWGRASS DRIVE								
(Street)								
I '	NY	11713						
(City)	(State)	(Zip)						
Name and Address of Reporting Person*								
Erani Dennis								
(Last)	(First)	(Middle)						
6000 ISLAND BOULEVARD								
APT. 2502								
(Street)								
AVENTURA	FL	33160						
(City)	(State)	(Zip)						

Explanation of Responses:

- 1. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$5.30 to \$5.55, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
- 2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$5.33 to \$5.54, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- 3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$5.34 to \$5.49, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
- 4. Reflects the total number of securities held by the Group. Only Albert Erani has a pecuniary interest in the shares being sold pursuant to this Form 4. None of the other members of the Group has a pecuniary interest in the shares being sold pursuant to this Form 4.

Remarks:

Alan A. Ades, Albert Erani, Glenn H. Nussdorf, Dennis Erani, Starr Wisdom and certain of their respective affiliates, including Organo PFG LLC, Organo Investors LLC, Dennis Erani 2012 Issue Trust, Alan Ades as Trustee of the Alan Ades 2014 GRAT, Albert Erani Family Trust dated 12/29/2012, GN 2016 Family Trust u/a/d August 12, 2016, GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 and RED Holdings, LLC, referred to collectively as the "Group", are parties to a Controlling Stockholders' Agreement dated December 10, 2018 with Organogenesis Holdings Inc. (the "Stockholders' Agreement"). The Stockholders' Agreement, the reporting persons may be deemed to be members of a group holding over 10% of the outstanding shares of common stock of the issuer for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. This is Form 4 No. 2 of 2 filed for the Group.

/s/ William R. Kolb, Attorneyin-Fact 06/08/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.